Food Tastes Different Now: What the Label Says, and Where the Studies Disagree

Taste disturbance is printed on the product information for these medicines. What it actually is, researchers have not settled: one large records study found it recorded more often, one sensory study measured it worse, the only randomised trial found it better. The useful fact here is about timing, not mechanism.

This is reporting on what product documents and published studies say. It is not medical advice, there is nothing here about doses, and no medicine is compared with another.

By Matt Cole. Editor: Sezen Soykut.

---

Key takeaways

• Taste disturbance is a listed side effect in the product information for these medicines — in the patient leaflet, "change in the way food or drink tastes". Food aversion is listed by nobody: zero mentions across seven European product informations, no match in US label data for three molecules [1][6].
• The evidence disagrees with itself. A 438,474-pair records study found taste disturbance recorded more often [2], a sensory study measured taste function worse [4], and the only randomised trial found taste recognition better [5]. A 2026 review found no support for "a consistent primary impairment of basic gustatory function" [3].
• Both regulators scope it early — "mainly seen in the dose-escalation period", "mainly reported within the first 12 weeks", often alongside nausea [1][6]. Follow-up is too short to say what lasts [3].

---

The small loss nobody prepares you for

It is rarely dramatic. The coffee you have made the same way every morning for ten years tastes thin, or metallic, or like someone else's. The thing you ate all last winter is suddenly hard to face. People report this quietly, because it sounds trivial said out loud. It is not: food you reach for without thinking is part of how a day holds together.

You are not imagining it — it is on the label

The European product information for these medicines lists taste disturbance, dysgeusia, among its undesirable effects. The patient leaflet puts it plainly: "change in the way food or drink tastes" [1].

The same medicine carries a different frequency depending on what it was prescribed for: licensed for weight management, taste disturbance sits in the "common" band — between 1 in 100 and 1 in 10 people in those trials; licensed for type 2 diabetes, it sits in "uncommon". The difference is in who was enrolled in the trials behind each label, not in the medicine [1].

The label records that it was reported. It does not say what it is.

The research disagrees with itself, openly

A 2026 study of routine medical records compared 438,474 matched pairs of adults with type 2 diabetes, taking these medicines against other diabetes medicines, and found a higher recorded risk of taste disturbance — hazard ratio 1.52, "consistent throughout the follow-up period". Its authors call it an association and ask for validation [2].

A 2025 study used sensory tests, not records. Measured taste function was significantly worse across all five basic tastes in 46 people taking these medicines against 46 matched controls, 85% scoring below their own control [4]. The same paper undercuts the obvious explanation: scores were better, not worse, in those reporting nausea and diarrhoea [4].

The only randomised trial points the other way entirely. Thirty women with polycystic ovary syndrome took semaglutide or placebo for 16 weeks, and taste recognition improved, from 11.9 to 14.4 points [5]. Small, women only, one condition, single-blinded. A 2026 mouse study found no change in taste-driven behaviour at all [7].

The 2026 review that read all of it landed where the mess points: "current evidence does not support a consistent primary impairment of basic gustatory function." Its reading: the experience is real but probably not a fault in the taste organ — "the same underlying phenomenon may be described as either 'taste abnormality' or 'reduced pleasure,' depending on the level and method of assessment" [3].

What is on no label at all

Across seven European product informations, the word aversion appears zero times. A cross-label query of the US drug-label data for three molecules returns none. No published paper is titled on it [1][6].

Taste disturbance is documented. Food becoming repellent is not. If you have read that these medicines make you hate a food, nobody has shown it — the review lists nausea-related aversion as one candidate among several it calls incompletely established [3].

The useful fact is about timing

Both regulators scope this early. The European product information footnotes taste disturbance as "mainly seen in the dose-escalation period" [1]. A US prescribing information for one of these medicines, licensed for weight management, is more specific: these events "were mainly reported within the first 12 weeks of treatment", "often co-reported with gastrointestinal events such as nausea, vomiting, and diarrhea" [6].

It clusters early, and travels with feeling unwell. The review adds that some symptoms "diminish or resolve over time", possibly "a reversible adaptive process" — while noting follow-up in the studies is short, so what persists is genuinely unknown [3]. (More on the early weeks: what to expect in the first month, and what helps with nausea.)

What to do with a food that has turned

None of this is evidence — ordinary sense, pointed by the timing.

• Stop forcing it, and park it rather than ban it. Eating something while you are struggling with it is how one bad experience becomes a lasting one. "Not today" and "never again" are different decisions, and only one is reversible. Re-test small, on a good day — not on the day you feel worst.
• Change one variable, not the whole food. Temperature, strength, how it is cooked, what it goes with. Unbearable hot is sometimes fine cold.
• One food is a quirk. Everything tasting wrong is worth mentioning to the person who prescribed the medicine.
• Mind the gap it leaves. If what you parked was a protein staple, something else has to carry it — our protein calculator gives you a target, and protein and training covers the rest.
• Write it down as you go — which food, which week, whether you felt sick that day. At your next appointment you describe a pattern instead of reconstructing one. That is where Gila earns its keep: thirty seconds a day still exists in March.

Loss, or progress?

Most people asking are really asking whether they are losing something. The honest answer is narrower than either reassurance or alarm: real enough to be printed on a label, measured in opposite directions by the people who measured it, loudest early, unknown in the long run.

A food you have parked is not a food you have lost — and what is worth watching is not any single morning's coffee, but whether the pattern widens or settles over weeks.

---

Sources

1. European Medicines Agency, product information (section 4.8, Undesirable effects; package leaflet section 4, Possible side effects) for the seven GLP-1 receptor agonist products authorised in the EU, including both the weight-management and the type 2 diabetes marketing authorisations of semaglutide. Retrieved from ema.europa.eu, 2026-10-18.
2. Zontag J, Zontag N. "Smell and Taste Disturbances Among Glucagon-Like Peptide-1 Receptor Agonist Users." JAMA Otolaryngology–Head & Neck Surgery 2026;152(8):758–765. https://doi.org/10.1001/jamaoto.2026.1498 — abstract only; full text paywalled.
3. Du J, Yang Z, Chen Y. "Altered eating experience during GLP-1 receptor agonist therapy: a sensory-liking-wanting framework for food preference and nutritional behaviour." Frontiers in Nutrition 2026;13:1870484. https://doi.org/10.3389/fnut.2026.1870484 — narrative review, open access.
4. Khan R, Doty RL. "GLP-1 receptor agonists significantly impair taste function." Physiology & Behavior 2025;291:114793. https://doi.org/10.1016/j.physbeh.2024.114793 — cross-sectional, 46 matched pairs; abstract only.
5. Jensterle M, Kovac J, Vovk A, Ferjan S, Battelino S, Battelino T, Janez A. "Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study." The Journal of Clinical Endocrinology and Metabolism 2025;111(1):e270–e280. https://doi.org/10.1210/clinem/dgaf278 — n=30, women only, all with PCOS, single-blinded, 16 weeks; taste recognition improved.
6. US prescribing information (section 6, Adverse Reactions) for liraglutide licensed for weight management, effective 2026-02-25. Retrieved via DailyMed, 2026-10-18. Cross-label query of the openFDA drug-label API for "food aversion" across semaglutide, tirzepatide and liraglutide: no matches, 2026-10-18. Europe PMC title search for "food aversion" or "taste aversion" with GLP-1 receptor agonists in the abstract: 0 results, 2026-10-18.
7. Acosta AA, Ellis H, Hsu FY, Yee KK, de Lartigue G, Alhadeff AL. "Chronic semaglutide alters ingestive behavior without impairing taste function in mice." Molecular Metabolism 2026;110:102410. https://doi.org/10.1016/j.molmet.2026.102410 — animal study.